How dosing might influence the conclusion in an antipsychotic polypharmacy effectiveness trial.

摘要

To the Editor: In the July 2011 issue of the Journal, Susan M. Essock et al. (1) provided valuable information on an important clinical paradox: the widespread use of antipsychotic polypharmacy in the treatment of schizophrenia, despite the lack of evidence to support it. However, the study had an essential limitation that was not addressed in the article: the matter of dosing.